Jim Simons Atreca, Inc. Transaction History

Renaissance Technologies LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.13 - $0.38 $1,833 - $5,358	14,100 Added 4.12%	356,024 $47,000
Q3 2023 Nov 14, 2023	BUY	$0.26 - $1.12 $6,838 - $29,456	26,300 Added 8.33%	341,924 $89,000
Q2 2023 Aug 11, 2023	BUY	$0.88 - $1.22 $16,104 - $22,326	18,300 Added 6.15%	315,624 $309,000
Q1 2023 May 12, 2023	BUY	$0.91 - $1.82 $12,740 - $25,480	14,000 Added 4.94%	297,324 $339,000
Q4 2022 Feb 13, 2023	SELL	$0.78 - $1.68 $95,591 - $205,889	-122,553 Reduced 30.19%	283,324 $227,000
Q3 2022 Nov 14, 2022	SELL	$1.59 - $2.74 $246,327 - $424,489	-154,923 Reduced 27.63%	405,877 $637,000
Q2 2022 Aug 12, 2022	BUY	$1.56 - $3.25 $304,824 - $635,050	195,400 Added 53.48%	560,800 $1 Million
Q1 2022 May 13, 2022	SELL	$1.61 - $5.2 $173,880 - $561,600	-108,000 Reduced 22.81%	365,400 $1.16 Million
Q4 2021 Feb 11, 2022	BUY	$2.87 - $6.29 $974,921 - $2.14 Million	339,694 Added 254.06%	473,400 $1.43 Million
Q3 2021 Nov 12, 2021	BUY	$4.91 - $9.07 $121,404 - $224,264	24,726 Added 22.69%	133,706 $833,000
Q2 2021 Aug 13, 2021	BUY	$7.82 - $13.8 $852,223 - $1.5 Million	108,980 New	108,980 $929,000

30.6K

Ticker BCEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,876,000
Description
Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-10...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.